Lilly takes charge for Zyprexa
- Share via
INDIANAPOLIS -- — Eli Lilly & Co. will take a big bite out of its third-quarter earnings with a $1.4-billion charge related to a government investigation over marketing practices for the antipsychotic medicine Zyprexa.
The drug maker said Tuesday that it would take a charge that equates to $1.29 a share because it was in advanced discussions with the U.S. attorney’s office for the Eastern District of Pennsylvania over U.S. marketing and promotional practices for the drug.
But a Lilly representative said the company wasn’t admitting it did anything wrong in selling the antipsychotic drug, its top revenue pro- ducer.
“All we’re doing today is taking a charge to earnings, so there is no admission or settlement or anything beyond that,” spokeswoman Marni Lemons said.
Patty Hartman, a spokeswoman for the U.S. attorney’s office, declined to comment on Lilly’s announcement.
Zyprexa brought in $4.7 billion in revenue last year.
More to Read
Inside the business of entertainment
The Wide Shot brings you news, analysis and insights on everything from streaming wars to production — and what it all means for the future.
You may occasionally receive promotional content from the Los Angeles Times.